Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARPAML: Talazoparib + Chemotherapy in Relapsed Pediatric AML
NCT05101551Phase 1Recruiting
- Start
- Feb 2023
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talazoparib in acute myeloid leukemia (AML). Primary endpoint: Dose Limiting Toxicity at 28 days. Started Feb 2023; status: recruiting.
02
Drugs
talazoparib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05101551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05101551.